Goldman Downgrades TEVA On Valuation

Symbols: TEVA
Tags: Goldman
Share

Analysts at Goldman Sachs downgrade Teva Pharmaceutical (NASDAQ: TEVA) from "conviction buy" to "buy." The target price for TEVA is set to $67.

According to Goldman Sachs, the downgrade in the rating is based on valuation.

TEVA’s shares lost 0.96% to $60.40. More Analyst Ratings here


 
 
< Previous
CYH Upgraded To Neutral
Next >
China Fire & Security Group (CFSG) Shares Fall 9%
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust

Special Offers:
Quick Cash Advance